[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-of-head-and-neck\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-of-head-and-neck":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,73,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100592591","discontinuation-of-tobacco-dependence-in-smoking-patients-with-squamous-cell-carcinoma-of-the-head-neck-district-multicenter-prospective-observational-study-100592591",false,"NCT06995417","Discontinuation of Tobacco Dependence in Smoking Patients With Squamous Cell Carcinoma of the Head-neck District: Multicenter Prospective Observational Study","STOP-HNC","Inclusion criteria.\n\n* Patients with SCCHN tumors of the oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, and paranasal sinuses.\n* Patients older than 18 years of age with SCCHN of these sites who are candidates for surgical\u002Fradiotherapy (RT)\u002Fradiochemotherapy (RTCT) treatment with curative intent (primary treatment).\n* Patients with SCCHN who are active smokers, or have quit smoking for less than 30 days, at the time of initiation of the process (visits and instrumental tests) that led to the diagnosis of cancer\n\nExclusion criteria\n\n* Patients with SCCHN cancer who have quit smoking for more than 30 days at the time of initiation of the diagnostic process.\n* Patients using only e-cigarettes at the time of initiation of the treatment process.\n* Patients with non-SCCHN cancer in recurrent metastatic stage and not eligible for curative purpose therapy.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","The primary objective of our study is to evaluate the effectiveness of a standardized clinical practice counseling strategy for promoting post-diagnosis smoking cessation among patients with SCCHN. Efficacy will be measured as the percentage of patients who succeed in sustained smoking cessation (\"sustained quitters,\" see below) at 6+1 months after enrollment, i.e., after the initiation of anti-smoking counseling.",[24],"Cancer of Head and Neck",[26,27],"Cancer Head&Neck","Smoker","NOT_YET_RECRUITING","2025-05-26",{"date":31,"type":32},"2025-05-29","ACTUAL",{"date":34,"type":20},"2025-06",{"date":36,"type":20},"2030-05",{"name":38,"class":39},"Azienda Ospedaliero-Universitaria Careggi","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":40},"100401659","a-multicenter-cancer-biospecimen-collection-study-100401659","NCT04510129","A Multicenter Cancer Biospecimen Collection Study","Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies","Inclusion Criteria:\n\n1. Subject must have a disease of interest. Specifically, subject must have one of:\n\n   1. head and neck squamous cell carcinoma (HNSCC)\n   2. non-small-cell lung cancer (NSCLC)\n   3. small cell lung cancer (SCLC)\n   4. urothelial carcinoma (UCC)\n   5. gastric or gastroesophageal junction adenocarcinoma\n   6. cervical cancer\n   7. esophageal squamous cell carcinoma (ESCC)\n   8. triple-negative breast cancer (TNBC)\n   9. hepatocellular carcinoma (HCC)\n   10. renal cell carcinoma (RCC)\n   11. colorectal cancer (CRC)\n2. Subject must have received, or be scheduled to receive, at least one dose of anti-PD-1\u002FPD-L1 immunotherapy for treatment of their cancer.\n3. Subject must have had, or will have, a tumor biopsy prior to treatment with anti-PD-1\u002FPD-L1 immunotherapy.\n4. Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the tumor prior to treatment with anti-PD-1\u002FPD-L1 immunotherapy.\n5. Willing to provide electronic informed consent per IRB-approved protocol.\n6. Able to speak, read, and comprehend English fluently.\n7. Subject is 18 years of age or older.\n8. Subjects must have sufficient tissue available to fulfill the specimen requirements of the study.\n\nExclusion Criteria:\n\n1. Inability or unwillingness to provide informed consent.\n2. Subject who does\u002Fdid not have one of the cancers listed above (other histologies).\n3. Subject has already participated in this trial.",{"count":49,"type":20},1650,"This study will collect de-identified tumor samples, with correlated clinical\u002Fdemographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.",[24,52,53,54,55,56,57,58,59,60,61],"Lung Cancer, Nonsmall Cell","Small-cell Lung Cancer","Urothelial Carcinoma","Gastroesophageal Junction Adenocarcinoma","Cervical Cancer","Esophageal Squamous Cell Carcinoma","Triple Negative Breast Cancer","Hepatocellular Carcinoma","Renal Cell Carcinoma","Colorectal Cancer","RECRUITING","2025-03-10",{"date":65,"type":32},"2025-03-12",{"date":67,"type":32},"2020-02-05",{"date":69,"type":20},"2027-02",{"name":71,"class":72},"Cofactor Genomics, Inc.","INDUSTRY",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100564507","artificial-intelligence-based-voice-assessment-of-children-and-adults-respiratory-conditions-100564507","NCT06630078","Artificial Intelligence-based Voice Assessment of Children and Adults Respiratory Conditions","Artificial Intelligence-based Voice Assessment of Children and Adults With Acute and Chronic Respiratory Conditions: Diagnostic and Prognostic Role","AIRWAY-VDAP","INCLUSION CRITERIA:\n\n* Children with bronchiolitis \\\u003C24 months of age clinically characterized according to the clinical definition accepted by international literature (Ralstone);\n* Children with asthma according to most recent GINA guidance (Global Initiative for Asthma, 2022) aged 6-12 years in a phase of proper control or during acute exacerbations;\n* Adults with upper aerodigestive tract chronic or acute clinical conditions;\n* Adults with pathologic diagnosis of head and neck cancer addressed to radiotherapy with or without chemotherapy for primary treatment of the tumor.\n\nEXCLUSION CRITERIA:\n\n* Children with comorbidities including genetic disorders;\n* Children with other chronic respiratory conditions (bronchodysplasia, cystic fibrosis);\n* Children with primary immunologic diseases;\n* Children with prematurity;\n* Children with other respiratory conditions not part of the inclusion criteria (examples: pneumonia, tonsillitis);\n* Adults over 70 years old or with neurological diseases;\n* Adults with syndromic disease;\n* Adults with malformations of upper aero-digestive tract;\n* Adults with history of head and neck surgery or not able to sustain a vocalism for more than 3 sec.","12 Months","70 Years",{"count":19,"type":20},"INTERVENTIONAL",[86],"NA","Acute and Chronic respiratory conditions represent a leading cause of death and morbidity in children and adults worldwide. The diagnosis of bronchiolitis and asthmatic exacerbations is based on clinical, and mostly subjective, clinical parameters with moderately accurate prognostic role. Patients undergoing neck radiotherapy need invasive assessments of larynx. A simple biomarker like Voice may facilitate the management of these conditions. Recent studies showed that VOICE may be used as a good and easy biomarker to diagnose and monitor several respiratory and non-respiratory conditions. A prospective study aimed to collected VOICE and other clinical data in adults and children with common acute and chronic respiratory conditions at high impact on healthcare systems will be performed. VOICE-omic data will be linked with clinical findings generating data integration, using artificial intelligence technology to develop a Decision Support Systems to provide the basis for non-invasive personalised early recognition, diagnosis, monitoring and prognosis of patients with these conditions.",[89,24,90,91,92],"Airway Disease","Radiotherapy","Bronchiolitis","Asthma","2024-10-17",{"date":95,"type":32},"2024-10-18",{"date":97,"type":20},"2024-11-30",{"date":99,"type":20},"2026-09-01",{"name":101,"class":39},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",2,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":84,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100421381","phase-2-interest-of-bilateral-basic-tongue-mucosectomy-assisted-by-robot-or-laser-in-combination-with-tonsillectomy-in-the-assessment-of-prevalent-cervical-lymphadenopathy-100421381","NCT04767048","Interest of Bilateral Basic Tongue Mucosectomy Assisted by Robot or Laser in Combination with Tonsillectomy in the Assessment of Prevalent Cervical Lymphadenopathy","Interest of Bilateral Basic Tongue Mucosectomy Assisted by Robot or Laser in Combination with Tonsillectomy in the Assessment of Prevalent Cervical Lymphadenopathy: a Randomized Phase II Study","RoboCUP","Inclusion Criteria:\n\n* Patient with a prevalent head and neck lymphadenopathy with positive or non-contributory fine needle aspiration, or having had an adenectomy revealing a metastasis of squamous cell carcinoma, a PET examination, an injected cervico-thoracic CT and an ENT work-up (nasofibroscopy) not finding a primary tumor\n* Performance Status \\\u003C 2\n* Patient aged 18 or over\n* Patient affiliated with social security system\n* Informed consent signed\n\nExclusion Criteria:\n\n* History of squamous cell carcinoma of the VADS or skin of the face.\n* History of cervico-facial radiotherapy\n* Primary tumor discovering during pan-endoscopy\n* Inexposable patient lead not to possible mucosectomy\n* Uncontrollable hemostasis disorders (contraindication to tonsillectomy and basic bilateral mucosectomy of language)\n* Distant metastases\n* Lymphadenopathy inoperable\n* Patient with a contraindication to radiotherapy\n* Pregnant or breastfeeding woman\n* Women of childbearing potential without effective contraception\n* Patient under guardianship or unable to give informed consent\n* Patient unable to undergo the trial follow-up for geographic, social or psychopathological reasons",{"count":112,"type":20},72,[114],"PHASE2","We are proposing a randomized phase II study to assess the benefit of bilateral robot-assisted or laser basal tongue mucosectomy in combination with tonsillectomy in the assessment of prevalent cervical lymphadenopathy",[24,117],"Adenopathy",[119,120],"mucosectomy","tonsil","2024-10-10",{"date":123,"type":32},"2024-10-15",{"date":125,"type":32},"2021-06-30",{"date":127,"type":20},"2029-03",{"name":129,"class":39},"Centre Francois Baclesse",5]